Astra
Executive Summary
Files supplemental NDA for Foscavir (foscarnet) injection as a second-line treatment for herpes simplex virus, firm announces Nov. 19. The SNDA is for the treatment of both HSV-1 and HSV-2 resistant to acyclovir (Burroughs Wellcome's Zovirax). Foscavir may be obtained for patients with herpes who are unresponsive to standard therapy under a compassionate use program originally set up for Foscavir before its Sept. 27, 1991 approval for AIDS-related cytomegalovirus retinitis.